本文選題：補(bǔ)腎健脾 + 化瘀�。� 參考：《中華中醫(yī)藥學(xué)刊》2017年05期

【摘要】：目的:探討補(bǔ)腎健脾化瘀法對(duì)原發(fā)性骨質(zhì)疏松癥(POP)的療效及對(duì)骨代謝指標(biāo)的影響。方法:將70例2010年1月—2014年12月收治的患者隨機(jī)分為對(duì)照組和治療組,每組35例。對(duì)照組采用碳酸鈣D3片口服,治療組在對(duì)照組基礎(chǔ)上聯(lián)合口服中醫(yī)補(bǔ)腎健脾化瘀藥方(黃芪,生地,淫羊藿,鹿角膠,龜膠,補(bǔ)骨脂,山藥,水蛭等)。3個(gè)月為1個(gè)療程,2個(gè)療程后觀察兩組患者骨痛、功能改善、骨密度、骨代謝指標(biāo)及不良反應(yīng)情況。結(jié)果:治療6個(gè)月后,治療組及對(duì)照組患者的骨痛評(píng)分、Oswestry功能障礙指數(shù)、腰椎L2-4及髖部的骨密度值較治療前均顯著減小(P0.01,P0.05),且治療組患者療效明顯優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療組治療后血清BALP及TRACP-5b較治療前及對(duì)照組明顯下降(P0.05),血清CT水平較治療前及對(duì)照組顯著增高(P0.05),血清Ca、P及BGP含量較治療前及對(duì)照組無明顯統(tǒng)計(jì)學(xué)差異(P0.05),而對(duì)照組治療前后各項(xiàng)骨代謝指標(biāo)變化均無統(tǒng)計(jì)學(xué)意義(P0.05)。治療期間兩組患者不良反應(yīng)發(fā)生率無明顯統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論:補(bǔ)腎健脾化瘀法聯(lián)合碳酸鈣D3能有效改善骨痛、患者功能及骨代謝,升高骨密度且不良反應(yīng)少,值得臨床推廣。
[Abstract]:Objective: to investigate the effect of tonifying kidney, strengthening spleen and removing blood stasis on primary osteoporosis and its effect on bone metabolism. Methods: 70 patients from January 2010 to December 2014 were randomly divided into control group and treatment group with 35 cases in each group. The control group was treated with calcium carbonate D3 tablets, and the treatment group was treated with traditional Chinese medicine prescription of tonifying kidney, strengthening spleen and removing blood stasis (Astragalus membranaceus, Shengdi, Epimedium, antler gum, turtle glue, psoralen, yam) on the basis of control group. After 2 courses of treatment, bone pain, function improvement, bone mineral density, bone metabolism index and adverse reaction were observed. Results: after 6 months of treatment, the Oswestry dysfunction index, bone mineral density of lumbar L2-4 and hip decreased significantly in the treatment group and the control group, and the curative effect of the treatment group was better than that of the control group. The difference was statistically significant (P 0.05). The levels of serum BALP and TRACP-5b in the treatment group were significantly lower than those before the treatment and the control group, while the serum CT level was significantly higher than that in the control group and the treatment group. There was no significant difference in the contents of serum caprop and BGP between the treatment group and the control group (P 0.05), while in the control group, there was no significant difference between the two groups. Before and after treatment, there was no significant change of bone metabolism index (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period (P 0.05). Conclusion: the method of tonifying kidney, invigorating spleen and removing blood stasis combined with calcium carbonate D3 can effectively improve bone pain, function and metabolism of bone, increase bone mineral density and have less adverse reactions, so it is worth popularizing in clinic.
【作者單位】： 安吉縣人民醫(yī)院骨科;
【基金】：浙江省科技廳項(xiàng)目(2015c33263)
【分類號(hào)】：R580

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳濱,裴國獻(xiàn);微創(chuàng)骨代謝指標(biāo)[J];中國矯形外科雜志;2005年07期

2 李曄;齊越峰;佟云;;老年男性骨質(zhì)疏松癥中骨代謝指標(biāo)的研究[J];中醫(yī)正骨;2007年06期

3 蔣英;;絕經(jīng)后婦女性激素對(duì)骨代謝指標(biāo)影響的初步觀察[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2007年24期

4 伍鳳莉;史紅巖;李燕春;吳宜勇;;苯卓昔芬對(duì)健康絕經(jīng)后婦女骨代謝及血脂的影響[J];中國新藥雜志;2009年16期

5 梁斌斌;張萌萌;張艷會(huì);劉洋;;436例女性骨代謝生物化學(xué)指標(biāo)測(cè)定的臨床意義[J];中國實(shí)驗(yàn)診斷學(xué);2011年04期

6 巴根;陳之光;;老年男性骨質(zhì)疏松癥患者外周血瘦素及骨代謝指標(biāo)表達(dá)分析[J];中國老年保健醫(yī)學(xué);2011年06期

7 趙瑯;柳富平;;不同運(yùn)動(dòng)項(xiàng)目對(duì)絕經(jīng)后婦女骨代謝影響的對(duì)比研究[J];福建體育科技;2013年02期

8 薛延輝;;老年男性維生素D水平與骨代謝指標(biāo)關(guān)系的探討[J];中國現(xiàn)代藥物應(yīng)用;2013年19期

9 洪玫,郝鐘林;血尿中骨代謝指標(biāo)檢測(cè)的臨床意義[J];國外醫(yī)學(xué).內(nèi)分泌學(xué)分冊(cè);1989年03期

10 李冰,金菊英;婦女絕經(jīng)前后骨代謝指標(biāo)的變化及激素補(bǔ)充療法對(duì)其影響[J];中國骨質(zhì)疏松雜志;2001年03期

相關(guān)會(huì)議論文 前10條

1 潘芬;陳世勇;;男性2型糖尿病患者骨代謝指標(biāo)檢測(cè)意義[A];2012年浙江省檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)年會(huì)論文集[C];2012年

2 韓玉昆;宋學(xué)茹;;絕經(jīng)前后骨代謝指標(biāo)與雌激素變化的關(guān)系[A];全國老年骨質(zhì)疏松專題學(xué)術(shù)研討會(huì)論文匯編[C];2000年

3 林梅;劉永健;胡~5麗;李文華;廖麗婭;符杰;;初診2型糖尿病患者的骨代謝指標(biāo)觀察[A];中華醫(yī)學(xué)會(huì)第三次骨質(zhì)疏松和骨礦鹽疾病中青年學(xué)術(shù)會(huì)議論文匯編[C];2011年

4 呂偉;馬艷;厲小梅;俞大亮;錢龍;李向培;汪國生;;類風(fēng)濕關(guān)節(jié)炎骨代謝指標(biāo)水平及臨床意義[A];第17次全國風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2012年

5 李紅;羅小云;;甲狀腺功能亢進(jìn)癥患者尿脫氧吡啶琳的變化[A];中華醫(yī)學(xué)會(huì)第六次全國內(nèi)分泌學(xué)術(shù)會(huì)議論文匯編[C];2001年

6 吳忠華;;骨代謝指標(biāo)的研究進(jìn)展及其應(yīng)用[A];2004年浙江省檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

7 龐東岳;史蕾;張弘弘;陳小紅;唐梅;胡吉;董吉祥;;男性2型糖尿病患者骨代謝指標(biāo)變化研究[A];中華醫(yī)學(xué)會(huì)第六次全國骨質(zhì)疏松和骨礦鹽疾病學(xué)術(shù)會(huì)議暨中華醫(yī)學(xué)會(huì)骨質(zhì)疏松和骨礦鹽疾病分會(huì)成立十周年論文匯編[C];2011年

8 沈曉o，

本文編號(hào)：1976029